| |
MESSAGE _ENGLISH VERSION_
|
|
| |
Appointment of Management Board Members of Ryvu Therapeutics S.A. for a
new term of office
The Management Board of Ryvu Therapeutics S.A. with its registered
office in Krakow, Poland _"Company", "Issuer"_ hereby informs that the
Supervisory Board of the Company appointed, effective June 25th, 2026,
the Management Board Members of the Company for a new 5-year term of
oficce in the following composition:
1. Mr. Paweł Przewięźlikowski - President of the Management Board;
2. Mr. Krzysztof Brzózka - Vice-President of the Management Board;
3. Mr. Kamil Sitarz - Vice-President of the Management Board;
4. Mr. Hendrik Nogai - Member of the Management Board;
5. Ms. Justyna Żółtek - Member of the Management Board.
Information on the appointed Management Board Members:
Mr. Paweł Przewięźlikowski
Mr. Przewiezlikowski is the Chief Executive Officer and founder of Ryvu
Therapeutics, responsible for strategic management, business and
corporate development of the company.
He is also the President of Supervisory Board at Ardigen and Member of
the Supervisory Board at Selvita. Before founding multiple companies in
the biotechnology sector _Ryvu, Ardigen, NodThera_, Mr. Przewiezlikowski
was a member of the executive team at technology company Comarch,
responsible for divisions involved in multiple industries including the
pharmaceutical industry. He was also the co-founder, the first CEO and
then the Vice President of the Supervisory Board of Interia.pl, the
third largest Internet portal in Poland.
Mr. Przewiezlikowski is a member of the Economic Council of the
Malopolska _Krakow_ region. He was awarded Knight's Cross of the Order
of Polonia Restituta for his contributions to the development of
Poland's business environment, as well as, EY Entrepreneur of the Year
2015 award in the New Technologies/Innovation category in Poland. Mr.
Przewiezlikowski holds an MBA from the joint program of the Teesside
University _United Kingdom_ and Krakow School of Economics _Poland_ as
well as master degree in computer science from AGH Technical University
in Krakow. He also studied IT at the Technical University in Berlin.
Mr. Paweł Przewięźlikowski, according to the statement submitted to the
Company, is not entered in the Register of Insolvent Debtors maintained
pursuant to the Act on the National Court Register and does not conduct
any activities competitive to Ryvu Therapeutics S.A., does not
participate in a company competitive to Ryvu Therapeutics S.A. as a
partner in a civil-law partnership, partnership or capital company, and
does not participate in any other legal person competitive to Ryvu
Therapeutics S.A. as a member of its governing body.
Mr. Krzysztof Brzózka
Krzysztof Brzozka, Ph.D., is the Chief Scientific Officer at Ryvu
Therapeutics. He has joined Ryvu Theraputics in 2007 and has applied his
interdisciplinary expertise ever since, in order to build a broad
pipeline of small molecule oncology therapeutics and a high throughput
discovery engine platform.
Dr. Brzozka is responsible for the management of the early pipeline
candidates, covering their full development until clinical phase. He is
also responsible for bringing into the clinic two Ryvu first-in-class
oncology programs: dual PIM/FLT3 inhibitor SEL24/MEN1703 and SEL120,
CDK8 inhibitor. Dr. Brzozka is also a member of the Supervisory Board of
Ardigen, a bioinformatics and precision medicine company, and
contributed to the founding of NodThera, a biotechnology company focused
on therapeutics related to inflammasome biology.
Dr. Brzozka holds a Ph.D. degree from Ludwig Maximilian University. He
also earned an MBA from the Stockholm University School of Business and
the Krakow University of Economics Business School. Dr. Brzozka
contributed to over 70 scientific publications and presentations in
areas of oncology, immunology, intracellular signaling and medicinal
chemistry. His publications were cited nearly 3500 times and published
in such journals as Science, Blood, Molecular Cell or Oncotarget.
Mr. Kamil Sitarz
Mr. Kamil Sitarz, Ph.D., MBA is the Chief Operating Officer and Member
of the Management Board of Ryvu Therapeutics. He holds executive
responsibility for Ryvu's clinical operations, program management, CMC,
and quality, as well as the company's financial performance and
portfolio governance.
Mr. Sitarz joined Ryvu in 2013, progressing through scientific and
operational leadership roles before being appointed Chief Operating
Officer and Management Board Member in 2020. Over the past decade, he
has been a central force in transforming Ryvu into a multi-program
clinical-stage organization.
Under his leadership, Ryvu has built and scaled a robust clinical
development organization, established strategic clinical collaborations
with leading global oncology partners including BioNTech and Menarini
Group, and strengthened the execution of complex oncology programs. In
parallel, he directly heads Ryvu's clinical execution division,
responsible for operational delivery across the company's clinical
programs and external collaborations.
Kamil Sitarz holds an M.Sc. in Biophysics from Jagiellonian University,
a Ph.D. in Human/Medical Genetics from Newcastle University, and an
Executive MBA from a joint program at Cracow School of Business CUE, EM
Normandie, and AESE Business School. He is the co-author of a dozen
scientific publications in peer-reviewed journals.
Mr. Kamil Sitarz, according to the statement submitted to the Company,
is not entered in the Register of Insolvent Debtors maintained pursuant
to the Act on the National Court Register and does not conduct any
activities competitive to Ryvu Therapeutics S.A., does not participate
in a company competitive to Ryvu Therapeutics S.A. as a partner in a
civil-law partnership, partnership or capital company, and does not
participate in any other legal person competitive to Ryvu Therapeutics
S.A. as a member of its governing body.
Mr. Hendrik Nogai
Dr. Hendrik Nogai, M.D., is the Chief Medical Officer at Ryvu
Therapeutics. Dr. Nogai is responsible for leading medical, clinical,
and regulatory functions to support and guide the development of the
company's pipeline.
Hendrik Nogai is a board-certified medical doctor in Hematology/Oncology
as well as in Internal Medicine, with almost 10 years of experience in
patient care and basic research in different academic settings,
including Charit - University Medicine Berlin, University Hospital in
Munich, and Zentralklinikum Augsburg. Besides his clinical expertise,
Dr. Nogai's brings 17 years of industry experience including business
consulting at Mercer Management Consulting/ Oliver Wyman, medical
advisory at Nordic Biotech Capital ApS, and positions of increasing
responsibility at Bayer AG, with his most recent role of Vice President,
Global Development Leader NTRK program.
Dr. Nogai has completed his Medical Studies at Charit - University
Medicine Berlin _Germany_, Ludwig-Maximilians University in Munich
_Germany_ and Harvard Medical School in Boston _USA_. He holds
adoctoral degree awarded by the Humboldt University of Berlin _Germany_
for his research on cell biology.
Mr. Hendrik Nogai, according to the statement submitted to the Company,
is not entered in the Register of Insolvent Debtors maintained pursuant
to the Act on the National Court Register and does not conduct any
activities competitive to Ryvu Therapeutics S.A., does not participate
in a company competitive to Ryvu Therapeutics S.A. as a partner in a
civil-law partnership, partnership or capital company, and does not
participate in any other legal person competitive to Ryvu Therapeutics
S.A. as a member of its governing body.
Ms. Justyna Żółtek
Ms. Justyna Żółtek joined the Company in 2021 as HR Director, taking
responsibility for establishing and developing the people function at
Ryvu Therapeutics. Since May 2024, she has served as Chief People
Officer, overseeing Administration, Payroll and HR areas.
During her time at the Company, she has developed and implemented a
comprehensive human capital management strategy, built the HR team, and
introduced key processes in leadership development, talent management,
and organizational culture transformation.
Ms. Żółtek brings over 15 years of professional experience gained in
international organizations, where she held regional and global HR roles
in sectors such as biotechnology, energy, construction, and new
technologies. She specializes in transformation projects, organizational
integrations, and building HR structures in fast-changing environments.
She was actively involved in the privatization process of EDF Polska
and, immediately prior to joining Ryvu, managed HR teams in Poland and
Bulgaria at a technology company undergoing a complex M_A process.
She is a graduate of the Cracow University of Economics and the Center
for Leadership - one of Poland's leading development programs for
business leaders.
Ms. Justyna Żółtek, according to the statement submitted to the Company,
is not entered in the Register of Insolvent Debtors maintained pursuant
to the Act on the National Court Register and does not conduct any
activities competitive to Ryvu Therapeutics S.A., does not participate
in a company competitive to Ryvu Therapeutics S.A. as a partner in a
civil-law partnership, partnership or capital company, and does not
participate in any other legal person competitive to Ryvu Therapeutics
S.A. as a member of its governing body.
Disclaimer: This English language translation has been prepared solely
for the convenience of English speaking readers. Despite all the efforts
devoted to this translation, certain discrepancies, omissions or
approximations may exist. In case of any differences between the Polish
and the English versions, the Polish version shall prevail. Ryvu
Therapeutics S.A., its representatives and employees decline all
responsibility in this regard.
|
|
|
RB: Powołanie Członków Zarządu Ryvu Therapeutics S.A. na nową kadencję / Appointment of
Management Board Members of Ryvu Therapeutics S.A. for a new term of office
